Introduction
Abnormal uterine bleeding (AUB) is any bleeding that
deviates from the normal cycle/frequency, length, and
quantity of menstrual bleeding, and represents one of
the most frequent health problems in women in the
reproductive period [1,2]. Also, it is a significant public
health issue. According to data from literature, the prev-
alence of this type of bleeding ranges from 3 to 30% [3].
Accurate knowledge of the physiology of menstru-
al bleeding is a prerequisite for establishing a timely
diagnosis and administering appropriate treatment for
abnormal uterine bleeding. A normal menstrual cycle
is defined as regular cyclical bleeding, which occurs ev-
ery 28 days, on average, and lasts from 4 to 7 days, with
an average blood loss of around 35 ml ( Table 1). This
cycle is the result of a complex interaction between the
hypothalamus, the anterior pituitary lobe, the ovaries,
and the endometrium. At each of these levels, hor -
mones are secreted, which enable or inhibit the release
of hormones at other levels. Less than 1.0% of women
have regular menstrual cycles that are shorter than 21
days or longer than 35 days [4].
Variations in the duration and intensity of menstru-
al bleeding are common at the beginning and at the
end of the reproductive period - in adolescence and be-
fore menopause. The frequency of anovulatory cycles
is the highest before 20 years of age and after 40 years
of age. During 12 to 18 months after menarche, men-
strual cycles are irregular, due to the immaturity of the
hypothalamic-pituitary-ovarian axis. Several years after
menarche, the length of the luteal phase of the cycle
becomes relatively constant (13 to 15 days). During the
period of 5 to 7 years following menarche, menstrual
cycles become regular, and their length and duration
do not significantly change during the reproductive
period, although, over the years, the length of the men-
strual cycle gradually shortens. During the period of 8
to 10 years before menopause, the frequency of ovula-
tory cycles gradually decreases [1-4].
If the function of the hypothalamic-pituitary-ovar -
ian axis is disrupted, and/or if a structural abnormality
of the uterus occurs (myomas, polyps, adenomyosis,
malignancy), or if there is a disorder in blood coagu-
lation (coagulopathies, iatrogenic causes), the normal
menstrual cycle is disrupted and abnormal uterine
bleeding occurs [5].
Abnormal uterine bleeding has a significant im-
pact on physical and mental health, as well as on the
emotional, sexual, and professional aspects of wom-
en’s lives, as they diminish their quality of life. Also, this
issue generates significant economic costs. It has been
estimated that direct medical costs for the treatment
of abnormal uterine bleeding in the United States of
UVOD
Patološko krvarenje iz materice (engl. abnormal uterine
bleeding -AUB) predstavlja svako krvarenje koje odstu-
pa od normalne cikličnosti/učestalosti, dužine trajanja
i obima menstrualnog krvarenja, i predstavlja jedan od
najčešćih poremećaja zdravlja kod žena u reproduk -
tivnom periodu [1,2]. Uz to, predstavlja i značajan jav -
no-zdravstveni problem. Prema podacima iz literature,
prevalencija ovih krvarenja iznosi 3 do 30% [3].
Precizno poznavanje osnova fiziologije menstrual-
nog ciklusa je uslov za postavljanje pravovremene di-
jagnoze i sprovođenje adekvatnog lečenja patološkog
krvarenja iz materice. Normalan menstrualni ciklus se
definiše kao regularno ciklično krvarenje, koje se javlja
na prosečno 28 dana, traje 4 do 7 dana, uz prosečan gu-
bitak krvi od oko 35 ml (Tabela 1). Ovaj ciklus je rezultat
složene interakcije između hipotalamusa, prednjeg re -
žnja hipofize, jajnika, i endometrijuma. Na svakom od
ovih nivoa stvaraju se hormoni, koji omogućavaju ili
sprečavaju oslobađanje hormona na drugim nivoima.
Manje od 1,0% žena imaju regularne menstruacione
cikluse koji traju kraće od 21 i duže od 35 dana [4].
Varijacije u dužini trajanja i intenzitetu menstrualnog
krvarenja su uobičajene na početku i kraju reproduktiv-
nog perioda - tokom adolescencije i pre nastupanja me-
nopauze. Učestalost anovulatornih ciklusa je najveća pre
20-te godine života i posle 40-te godine života. Tokom 12
do 18 meseci nakon menarhe, menstruacioni ciklusi su
iregularni, usled nezrelosti hipotalamo-hipofizno-ovarijal-
ne osovine. Nekoliko godina nakon menarhe, dužina lu-
tealne faze ciklusa postaje relativno konstantna (13 do 15
dana). Tokom 5 do 7 godina nakon menarhe, menstruaci-
oni ciklusi postaju regularni i njihova dužina i trajanje se ne
menjaju značajno tokom reproduktivnog perioda, iako se
sa godinama dužina trajanja menstruacionih ciklusa po-
lako smanjuje. Tokom perioda od 8 do 10 godina pre me-
nopauze, učestalost ovulatornih ciklusa se smanjuje [1 - 4].
Ukoliko dođe do poremećaja funkcije hipotala-
mo-hipofizne osovine i/ili strukturalnog poremećaja
materice (miomi, polipi, adenomioza, malignitet), ili
poremećaja u koagulaciji krvi (koagulopatije, jatrogeni
uzroci), remeti se normalan menstrualni ciklus i nastaje
patološko krvarenje [5].
Tabela 1. Karakteristike normalnog menstrualnog krvarenja
Table 1. Characteristics of normal menstrual bleeding
Interval između ciklusa / Interval between cycles 28 (21 - 35) dana / days
Dužina trajanja krvarenja / Duration of bleeding 4 - 7 dana / days
Obim krvarenja / Bleeding volume 35 (20 - 80) ml
Sparić R. i sar.
418 Decembar 2021. | Volumen 2 / Broj 4 | SrpSki medicinSki čaSopiS LekarSke komore
patološko krvarenje iz materice kod žena u reproduktivnom periodu
abnormal uterine bleeding in women of reproductive age
America amount to roughly 1 billion dollars per year,
while indirect costs, stemming from absence from
work and decrease in social and life activity, amount to
approximately 12 billion dollars annually [6].
The aim of this paper is to present the current clas-
sification, as well as the bases of diagnosis and treat -
ment of abnormal uterine bleeding.
Keywords
“menstrual bleeding” , “abnormal uterine
bleeding” , “PALM-COEIN classification” , “leiomyoma” ,
“endometrial polyp” , “adenomyosis” , “gynecological
malignancies” , “coagulopathy” , “diagnostics of abnor-
mal uterine bleeding” , and “treatment of abnormal
uterine bleeding” . The database search and the meth-
od of publication selection and inclusion into this
study are presented in Figure 1.
Patološka krvarenja iz materice imaju značajan uti-
caj na fizičko i mentalno zdravlje, kao i na emotivni,
seksualni i profesionalni aspekt života žena, smanjujući
i njihov kvalitet života. Takođe, ova krvarenja uzrokuju
značajne materijalne troškove. Procenjeno je da direk-
tni troškovi njihovog lečenja u Sjedinjenim Američkim
Državama iznose oko jednu milijardu dolara godišnje,
dok indirektni troškovi koji proističu iz izostanka sa
posla, smanjenja društvene i životne aktivnosti iznose
oko 12 milijardi dolara godišnje [6].
Cilj ovog rada je da se prikaže savremena podela,
kao i osnovi dijagnostike i lečenja patoloških krvarenja
iz materice.
METODE
U radu su prikazani podaci iz radova selektovanih pre -
traživanjem PubMed baze korišćenjem kombinacije
ključnih reči: “menstrual bleeding”, “abnormal uterine
bleeding”, “PALM-COEIN classification”, “leiomyoma”, “en-
Slika 1. PRISMA dijagram pretraživanja i odabira publikacija Figure 1. PRISMA diagram of the publications search and selection
Pretraživanje naučnih radova i publikacija / Research papers and publications search
Pretraživanje / Research
Radovi pronađeni u bazi podataka /
Papers found in the database
(n = 5.669)
Uključivanje / Inclusion
Radovi isključeni pre daljeg pretraživanja /
Papers excluded before further search
– Radovi označeni kao neodgovarajući putem alata za pretraživanje /
Papers marked as not suitable with the aid of the search tool
(n = 5.243 )
– Radovi označeni kao neodgovarajući iz drugih razloga /
Papers marked as not suitable for other reasons
(n = 268)
Pretraženi radovi /
Papers searched
(n = 158)
Isključeni radovi /
Papers excluded
(n = 31)
Radovi koji su detaljno pretraženi i razmotreni za uključivanje /
Papers searched in detail and considered for inclusion
(n = 127)
Pretraženi radovi /
Papers meeting the inclusion criteria
(n = 31)
Uključeni radovi/
Papers included
(n = 31)
Sparić R. et al.
Serbian JournaL of the m edicaL c hamber | Volume 2 / No. 4 | December 2021. 419
patološko krvarenje iz materice kod žena u reproduktivnom periodu
abnormal uterine bleeding in women of reproductive age
Current nomenclature of menstrual cycle disor-
ders and abnormal uterine bleeding (FIGO 2011)
For the purpose of achieving a uniform classification
of menstrual cycle disorders, in 2011, the Internation-
al Federation of Gynecology and Obstetrics (FIGO) in-
troduced a classification of these disorders under the
name PALM-COEIN [1-3]. This acronym denotes indi-
vidual causes of abnormal uterine bleeding. The caus-
es listed in the first part of the acronym (PALM) have a
pathological/anatomical cause in the reproductive or -
gans that can be diagnosed using imaging techniques
and/or histopathological examination [1,2,4,7]. The
causes listed in the second part of the acronym (COEIN)
represent a group of dysfunctional disorders and they
cannot be diagnosed using imaging techniques [1-4].
Endometrial polyp
A polyp is a lesion which is formed as the result of lo -
calized endometrial tissue growth. It is composed of
glands, stroma, and blood vessels, and is covered with
epithelium. It is most commonly encountered in women
in the reproductive period, and the frequency of the oc-
currence of polyps increases with age. It is believed that
estrogens play a key role in their formation [8 ]. Abnor-
mal uterine bleeding, caused by polyps, is manifested as
intermenstrual bleeding, hypermenorrhea, metrorrha-
gia or postmenopausal bleeding, and may also be linked
to dysmenorrhea. However, just like myomas, polyps are
most commonly asymptomatic [8,9]. They are frequent
in infertile patients and those treated with tamoxifen.
Most of the endometrial polyps are benign, although,
in postmenopause, in 1.5 to 4.5% of the cases, they are
malignant [8,9]. Polyps smaller than 1 cm may sponta-
neously regress. They are diagnosed by ultrasound or
with hysteroscopy. Polyps are treated by surgical-hys-
teroscopic resection or by explorative curettage [9].
Adenomyosis
Adenomyosis is characterized by the presence of en-
dometrial tissue (glands and stroma) in the myometri-
um. The presence of ectopic endometrial tissue leads
to hypertrophy of the surrounding myometrium, caus-
ing diffuse enlargement of the uterus. It occurs focally
or diffusely in the uterus, and its greatest frequency is
in women in their forties. The most significant factor for
the occurrence of adenomyosis is multiparity, but it is
believed that all factors contributing to the penetration
of endometrial glands and the stroma through the basal
layer of the endometrium, influence the development of
endometriosis (curettage of the uterine cavity, cesarean
section, miscarriage). Bleeding caused by adenomyosis
occurs as the result of uterine contractility impairment. It
dometrial polyp”, “adenomyosis”, “gynecological mali-
gnancies”, “coagulopathy”, “diagnostics of abnormal ute-
rine bleeding” , i “treatment of abnormal uterine bleeding”.
Pretraživanje baze podataka, način odabira i uključiva-
nja publikacija u ovaj rad prikazani su u Grafikonu 1.
Savremena nomenklatura poremećaja menstru-
alnog ciklusa i patoloških krvarenja iz materice
(FIGO 2011)
U cilju postizanja jedinstvene klasifikacije patoloških
krvarenja iz materice, Međunarodna federacija gineko-
loga i akušera (engl. International Federation of Gyneco-
logy and Obstetrics - FIGO) je, 2011. godine, uvela klasi-
fikaciju ovih poremećaja pod nazivom PALM-COEIN [1-
3]. Sam akronim označava pojedine uzroke patološkog
krvarenja iz materice. Uzroci nabrojani u prvom delu
akronima (PALM) imaju patološko-anatomski supstrat
na nivou genitalnih organa koji se može dijagnostiko -
vati primenom imidžing metoda i/ili histopatološkim
pregledom [1,2,4,7]. Uzroci nabrojani u grupi COEIN
uključuju difsunkcionalne poremećaje i ne mogu se di-
jagnostikovati primenom imidžing metoda [1-4].
Endometrijalni polip
Polip predstavlja promenu nastalu usled lokalizovanog
rasta tkiva endometrijuma, sastavljenu od žlezda, stro -
me i krvnih sudova, i pokrivenu epitelom. Najčešće se
sreće kod žena u reproduktivnom periodu, a učestalost
polipa se povećava sa godinama. Smatra se da estrogeni
igraju ključnu ulogu u njihovom nastanku [8]. Patološko
krvarenje uzrokovano polipima se manifestuje kao in-
termenstrualno krvarenje, hipermenoreja, metroragija
ili postmenopauzalno krvarenje, a može biti povezano
i sa dismenorejom. Ipak, kao i miomi, polipi su najčešće
asimptomatski [8,9]. Česti su kod infertilnih pacijentki-
nja i onih koje primaju tamoksifen. Najveći broj polipa
endometrijuma su benigni, mada su u postmenopauzi
u 1,5 do 4,5% slučajeva maligni [8,9]. Polipi manji od 1
cm mogu spontano regredirati. Dijagnostikuju se ultra-
zvukom ili histeroskopski. Polipi se leče hirurški-histero-
skopskom resekcijom ili eksplorativnom kiretažom [9].
Adenomioza
Adenomiozu karakteriše prisustvo tkiva endometrijuma
(žlezda i strome) u miometrijumu. Prisustvo ektopičnog
endometrijalnog tkiva dovodi do hipertrofije okolnog
miometrijuma, uzrokujući difuzno uvećanje materice.
Javlja se fokalno ili difuzno u materici, a najveću uče -
stalost ima u petoj deceniji života. Najznačajniji faktor
za nastanak adenomioze je multiparitet, ali se smatra
da svi faktori koji doprinose penetraciji endometrijalnih
žlezda i strome kroz bazalni sloj endometrijuma, utiču
na nastanak endometrioze (kiretaža materične šupljine,
Sparić R. i sar.
420 Decembar 2021. | Volumen 2 / Broj 4 | SrpSki medicinSki čaSopiS LekarSke komore
patološko krvarenje iz materice kod žena u reproduktivnom periodu
abnormal uterine bleeding in women of reproductive age
carski rez, spontani pobačaj). Krvarenje uzrokovano
adenomiozom nastaje kao posledica poremećaja kon-
traktilnosti materice. Najčešće se manifestuje menora-
gijom i obično je povezano sa izraženom dismenore -
jom [10]. Adenomioza se dijagnostikuje ultrazvukom i
nuklearnom magnetnom rezonancom. Definitivna dija-
gnoza se postavlja histopatološkim pregledom. Medi-
kamentno lečenje uključuje primenu progesteronskih
preparata, agonista gonadotropin-oslobađajućeg hor -
mona (engl. gonadotropin-releasing hormone - GnRH) i
inhibitora aromataze. Fokalna ognjišta adenomioze se
mogu lečiti hirurškom resekcijom. Kod žena koje nisu
zainteresovane za reprodukciju, lečenje je moguće
sprovesti embolizacijom materičnih arterija [11].
Leiomiom
Leiomiomi, miomi ili fibromi su benigni tumori pore -
klom od mišićnih ćelija miometrijuma. Predstavljaju
najčešće benigne tumore ženskih reproduktivnih or -
gana. Klinička slika varira od potpunog odsustva su-
bjektivnih tegoba do brojnih simptoma, koji mogu
imati značajan uticaj na zdravlje žene. Manje od 50,0%
mioma su simptomatski, a najčešći simptom je pato -
loško krvarenje iz materice [7,12–15]. Mogu biti poje -
dinačni ili multipli, a u oko 97,0% slučajeva su lokalizo-
vani u telu materice. U odnosu na anatomske slojeve
zida materice ovi tumori se dele na submukozne, in-
tramuralne, subserozne, i intraligamentarne (miomi
lokalizovani između listova širokih materičnih veza).
Na Slici 2 prikazana je FIGO podela mioma na osnovu
Slika 2. Tipovi mioma po FIGO klasifikaciji Figure 2. Types of myomas according to the FIGO classification
most commonly manifests as menorrhagia and is usually
connected to marked dysmenorrhea [10]. Adenomyosis
is diagnosed with ultrasound and nuclear magnetic res-
onance imaging. Definitive diagnosis is established by
histopathological examination. Medicamentous treat -
ment includes the application of progesterone-based
medicaments, gonadotropin-releasing hormone (GnRH)
agonists, and aromatase inhibitors. Focal areas of adeno-
myosis can be treated with surgical resection. In women
not interested in reproduction, it is possible to perform
treatment by embolizing uterine arteries [11].
Leiomyomas
Leiomyomas, myomas or fibromas are benign tumors
originating from muscular cells of the myometrium.
They are the most common benign tumors of female re-
productive organs. The clinical presentation varies from
complete absence of subjective complaints to numer -
ous symptoms, which may significantly affect the wom-
an’s health. Less than 50.0% are symptomatic, and the
most frequent symptom is abnormal uterine bleeding
[7,12–15]. They can be solitary or multiple, and in around
97.0% of the cases, they are localized in the body of the
uterus. In relation to the anatomical layers of the uterine
wall, these tumors are classified as submucosal, intramu-
ral, subserosal, and intraligamentous (myomas localized
between the leaves of the broad uterine ligaments).
Figure 2 shows the FIGO classification of myomas based
on localization [1-3]. The nomenclature of myomas, by
type, based on this classification is presented in Table 2.
Sparić R. et al.
Serbian JournaL of the m edicaL c hamber | Volume 2 / No. 4 | December 2021. 421
patološko krvarenje iz materice kod žena u reproduktivnom periodu
abnormal uterine bleeding in women of reproductive age
lokalizacije [1-3]. Nomenklatura mioma po tipovima na
osnovu ove podele prikazana je u Tabeli 2.
Mehanizmi kojima miomi utiču na pojavu patološ-
kih krvarenja iz materice su različiti, a u velikoj meri za-
vise i od njihove veličine, broja i lokalizacije. Kod žena
sa patološkim krvarenjem iz materice, najčešće se di-
jagnostikuju intrakavitarni (miomi u šupljini materice),
submukozni miomi i veliki intramuralni miomi [16]. Ovi
miomi povećavaju ukupnu površinu šupljine materice
prekrivenu endometrijumom, dovode do iregularne
deskvamacije endometrijuma i iregularnih kontrak -
cija materice, izazivajući iregularna i obilna materična
krvarenja [17]. Pored toga, novija saznanja ukazuju na
značaj neoangiogeneze, povišenih nivoa vazoaktivnih
supstanci i faktora rasta, kao i koagulacionih promena,
koji zajednički utiču na pojavu patoloških krvarenja
kod žena sa miomima [18]. Lečenje mioma je medi-
kamentno (kombinovana oralna kontracepcija, GnRH
agonisti i antagonisti) ili hirurško (miomektomija, histe-
rektomija), u zavisnosti od karakteristika mioma, godi-
na starosti i pariteta pacijentkinje [19]. Kod žena koje
nisu zainteresovane za reprodukciju, lečenje je moguće
sprovesti embolizacijom materičnih arterija [20].
Malignitet i hiperplazija
Maligne bolesti ženskih reproduktivnih organa koje
mogu uzrokovati krvarenje uključuju oboljenja vulve,
vagine, grlića materice, endometrijuma, tela materice,
jajnika i jajovoda. Najčešći uzroci patoloških krvarenja
su maligniteti materice.
Karcinom grlića materice se manifestuje kontak -
tnim, intermenstrualnim ili potpuno acikličnim krvare -
njem, te je isključivanje ovog oboljenja značajan deo
The mechanisms through which myomas affect the
occurrence of abnormal uterine bleeding vary and de-
pend, to a great extent, on the size of the myomas, their
number, and localization. In women with abnormal
uterine bleeding, the following myomas are most com-
monly diagnosed: intracavitary (myomas in the uterine
cavity), submucosal, and large intramural myomas [16].
These myomas enlarge the overall surface of the uter -
ine cavity covered with endometrium, lead to irregular
desquamation of the endometrium and to irregular
contractions of the uterus, thereby causing irregular
and profuse uterine bleeding [17]. Also, recent discov -
eries indicate the significance of neoangiogenesis, ele-
vated levels of vasoactive substances and growth fac -
tors, and of coagulation changes, which together affect
the occurrence of abnormal bleeding in women with
myomas [18]. Treatment of myomas is medicamentous
(combined oral contraceptives, GnRH agonists and an-
tagonists) or surgical (myomectomy, hysterectomy),
depending on the characteristics of the myomas and
on the age and parity of the patient [19]. In women
not interested in reproduction, it is possible to perform
treatment by embolizing uterine arteries [20].
Malignancy and hyperplasia
Malignant diseases of female reproductive organs that
may cause bleeding include malignancies affecting
the vulva, the vagina, the cervix, the endometrium, the
uterine body, the ovaries and the oviducts The most
common causes of abnormal uterine bleeding are
uterine malignancies.
Cervical carcinoma manifests as contact, intermen-
strual or completely acyclic bleeding, which is why it
Tabela 1. Karakteristike normalnog menstrualnog krvarenja Table 1. Characteristics of normal menstrual bleeding
SM - submukozni /
SM - submucosal
0 Intrakavitarni miomi na peteljci / Intracavitary pedunculated myomas
1 <0% intramuralni / <50% intramural
2 ≥50% intramuralni / ≥50% intramural
O - ostali/
O - other
3 U kontaktu sa endometrijumom, 100% intramuralni / In contact with the endometrium, 100% intramural
4 Intramuralni / Intramural
5 Subserozni ≥50% intramuralni / Subserosal ≥50% intramural
6 Subserozni <50% intramuralni / Subserosal <50% intramural
7 Subserozni na peteljci / Pedunculated subserosal
8 Drugi (cervikalni, intraligamentarni, parazitni)i / Other (cervical, intraligamentous, parasitic)
Hibridni leiomiomi (u kontaktu
kako sa endometrijumom, tako
i sa serozom materice)/ Hybrid
leiomyomas (in contact both
with the endometrium and with
the uterine serosa)
Obeležavaju se sa dva broja odvojena crtom (-). Prvi broj označava odnos mioma sa endometrijumom, a drugi odnos mioma sa
serozom materice. / They are marked with two numbers separated by a hyphen (-). The first number marks the relation between the
myoma and the endometrium, while the other one designates the relation between the myoma and the uterine serosa.
Na primer, miom 2-5 je submukozni i subserozni, pri čemu je manje od 50% volumena mioma u odnosu sa endometrijumom i
peritonealnom šupljinom. / For example, a myoma marked 2-5 is submucosal and subserosal, with less than 50% of the myoma
volume in contact with the endometrium and the peritoneal cavity.
Sparić R. i sar.
422 Decembar 2021. | Volumen 2 / Broj 4 | SrpSki medicinSki čaSopiS LekarSke komore
patološko krvarenje iz materice kod žena u reproduktivnom periodu
abnormal uterine bleeding in women of reproductive age
is important to rule out this disease, as a part of the
process of diagnosing the cause of abnormal uterine
bleeding [21]. Abnormal bleeding can be caused by
different endometrial disorders, such as cystic and ad-
enomatous hyperplasia, endometrial intraepithelial
neoplasia (EIN), and endometrial carcinoma [4,22]. The
most frequent symptom of endometrial carcinoma is
abnormal uterine bleeding. Although it most frequent-
ly occurs in women in their sixties, in around 15.0% of
the cases it is encountered in premenopausal women,
and in 3.0% to 5.0% of the cases in women younger
than 40 years. Uterine sarcomas usually occur in old-
er women in menopause, and they clinically manifest
as abnormal uterine bleeding and progressive en-
largement of the uterus. Ovarian estrogen producing
tumors (most commonly granulosa cell tumors) may
manifest as abnormal uterine bleeding [2-4,23].
Coagulopathy
Abnormal uterine bleeding may be the first clini-
cal manifestation of hematological diseases. Around
13.0% of women with profuse menstrual bleeding
have some form of coagulation disorder, of which the
most common one is von Willebrand’s disease [24].
Coagulopathy represents one of the most frequent
causes of menorrhagia [25]. Diseases leading to plate -
let deficiency, which can be the cause of abnormal
uterine bleeding, include leukemia, severe forms of
sepsis, and idiopathic thrombocytopenic purpura. He -
mophilia A and B are X-related recessive deficiencies
of coagulation factor VIII and coagulation factor IX
[24-26]. Women who are carriers of this disease have
decreased levels of factor VIII and factor IX, which may
manifest as menorrhagia. Less frequently, hereditary
coagulopathies that include a disorder in other coag-
ulation factors (V, VII, X, XI and XIII) may manifest as
menorrhagia. Disorders of liver function in alcoholism,
as well as chronic liver diseases, may result in a coagu-
lation factor production disorder and the occurrence
of abnormal bleeding [24].
Around 5.0% to 20.0% of adolescent young women
who experience abnormal uterine bleeding have some
form of coagulopathy. This is why coagulation status
testing is especially significant in women of this age [25].
Detailed analysis of the coagulation status pres-
ents an indispensable part of the diagnostic protocol
in women with abnormal uterine bleeding, and the
treatment is hematological [24,25].
Ovulatory dysfunction
One of the causes of abnormal uterine bleeding, which
occurs in the period after menarche and in perimeno -
pause, is ovulatory dysfunction. It develops as the result
postupka dijagnostike uzroka patoloških krvarenja iz
materice [21]. Patološko krvarenje može biti uzrokova-
no različitim poremećajima endometrijuma, kao što su
cistična i adenomatozna hiperplazija, endometrijalna
intraepitelna neoplazija (EIN) i karcinom endometri-
juma [4,22]. Najčešći simptom karcinoma endometri-
juma je patološko krvarenje iz materice. Iako se najče -
šće javlja tokom sedme decenije života, u oko 15,0%
slučajeva se sreće kod premenopauzalih žena, a u oko
3,0% do 5,0% slučajeva kod žena mlađih od 40 godina.
Sarkomi materice se obično javljaju kod starijih žena u
menopauzi, a klinički se manifestuju patološkim krva-
renjem iz materice i progresivnim uvećanjem materice.
Tumori jajnika koji produkuju estrogen (najčešće gra-
nuloza-ćelijski tumori) mogu se manifestovati patološ-
kim krvarenjem iz materice [2-4,23].
Koagulopatija
Patološko krvarenje iz materice može biti prva klinič -
ka manifestacija hematoloških oboljenja. Oko 13,0%
žena sa obilnim menstrualnim krvarenjem ima neki ko -
agulacioni poremećaj, od kojih je najzastupljenija von
Vilebrandova bolest [24]. Koagulopatija predstavlja
jedan od najčešćih uzroka menoragije [25]. Oboljenja
koja dovode do deficita trombocita, a mogu biti i uzrok
patoloških krvarenja iz materice, uključuju leukemi-
ju, teške oblike sepse, idiopatsku trombocitopenijsku
purpuru. Hemofilija A i B su X-vezani recesivni deficiti
faktora koagulacije VIII i faktora koagulacije IX [24-26].
Žene koje su prenosioci ovih bolesti imaju snižene
nivoe faktora VIII i faktora IX, što se može manifesto -
vati menoragijom. Ređe, nasledne koagulopatije koje
uključuju poremećaj ostalih faktora koagulacije (V, VII,
X, XI i XIII), mogu se manifestovati menoragijom. Pore-
mećaji funkcije jetre kod alkoholizma, kao i njena hro -
nična oboljenja mogu imati za posledicu poremećaj
produkcije faktora koagulacije i nastanak patološkog
krvarenja [24].
Oko 5,0% do 20,0% adolescentkinja kod kojih se
pojavi patološko krvarenje iz materice imaju neku koa-
gulopatiju. Zbog toga je ispitivanje koagulacinog statu-
sa naročito značajno kod žena ovog životnog doba [25].
Detaljno ispitivanje koagulacionog statusa pred-
stavlja neizostavni deo dijagnostičkog protokola kod
žena sa patološkim krvarenjima iz materice, a lečenje
je hematološko [24,25].
Ovulatorna disfunkcija
Jedan od uzroka patoloških krvarenja, koja se javljaju
u periodu nakon menarhe i u perimenopauzi, jeste
ovulatorna disfunkcija. Nastaje kao posledica poreme -
ćaja funkcije hipotalamo-hipofizno-ovarijalne osovine,
sa kontinuiranom produkcijom estrogena i izostankom
Sparić R. et al.
Serbian JournaL of the m edicaL c hamber | Volume 2 / No. 4 | December 2021. 423
patološko krvarenje iz materice kod žena u reproduktivnom periodu
abnormal uterine bleeding in women of reproductive age
of a disturbance in the functioning of the hypothalam-
ic-pituitary-ovarian axis, with continuous production
of estrogen and absence of ovulation, corpus luteum
formation and progesterone secretion in the ovaries.
Estrogen stimulation leads to continuous proliferation
of the endometrium, which, at some point, due to in-
sufficient vascularization, necrotizes. As the result of
this disorder, so-called breakthrough bleeding occurs.
Such anovulatory bleeding is most frequent during the
first few years after menarche and in perimenopause. In
adolescence, the cause of anovulation is the immaturi-
ty of the hypothalamic-pituitary-gonadal axis and the
absence of positive feedback by estradiol, which causes
peak LH (luteinizing hormone). In perimenopause, the
cause of this type of bleeding is ovarian insufficiency.
Especially profuse bleeding occurs after a prolonged
period of endometrial exposure to estrogens, which is
usually found in adolescent young women after men-
arche, patients with polycystic ovary (PCO) syndrome,
obese, and perimenopausal women [4,26].
Ovulatory dysfunction can manifest as amenor -
rhea, while anovulatory bleeding may manifest as ol-
igomenorrhea, intermenstrual bleeding or hypermen-
orrhea. In women with regular menstrual cycles, ovula-
tion is absent in 20.0% of the cases.
The most common cause of anovulatory bleeding
during the reproductive period in women is the poly -
cystic ovary syndrome (PCOS). A disturbance of the hy-
pothalamic-pituitary function is a less common cause.
Additionally, other hormonal disbalances may be ac -
companied by anovulatory bleeding, such as diseases
of the thyroid gland (hypothyroidism, hyperthyroid-
ism), diseases of the adrenal glands, and diabetes mel-
litus [27,28]. Hyperprolactinemia and elevated levels of
cortisol (Cushing’s syndrome) can also lead to anovu-
lation. Less frequently, the causes can be eating disor -
ders (anorexia, bulimia), chronic disease, alcoholism,
drug abuse, and stress [4,27,28].
Iatrogenic causes
Abnormal uterine bleeding resulting from iatrogenic
causes is the consequence of taking medication, most
commonly oral contraceptives, selective modulators
of estrogen receptors, GnRH agonists and antagonists,
digitalis, and anticonvulsants. Drugs cause abnormal
bleeding, either by disrupting the function of the hy -
pothalamic-pituitary-gonadal axis or by causing fluc -
tuations in the levels of circulating hormones.
Hyperprolactinemia may be the result of the effect
of antipsychotics acting as dopamine antagonists at
the level of the central nervous system (risperidone)
[4,29]. This type of abnormal bleeding may occur in
patients who use combined hormonal contraception
ovulacije, formiranja žutog tela i sekrecije progestrona
u jajniku. Estrogena stimulacija dovodi do kontinuira-
ne proliferacije endometrijuma, koji u nekom trenutku,
usled nedovoljne vaskularizacije, podleže nekrozi. Kao
posledica ovog poremećaja nastaje tzv. probojno krva-
renje. Ovakva anovulatorna krvarenja su najčešća to -
kom prvih nekoliko godina nakon menarhe i u perime-
nopauzi. U adolescenciji, uzrok anovulacija je nezrelost
hipotalamo-hipofizno-gonadne osovine i izostanak
pozitivne povratne sprege estradiola, koja uzrokuje
pik LH-a (luteinizirajućeg hormona). U perimenopauzi,
uzrok ove vrste krvarenja je ovarijalna insuficijencija.
Naročito obilna krvarenja se javljaju nakon prolongira-
nog perioda ekspozicije endometrijuma estrogenima,
što se obično sreće kod adolescentkinja nakon menar-
he, pacijentkinja sa PCO (engl. polycystic ovary) sindro-
mom, gojaznih, kao i perimenopauzalnih žena [4,26].
Ovulatorna disfunkcija se može manifestovati i
amenorejom, a anovulatorna krvarenja oligomenore -
jom, intermenstrualnim krvarenjem ili hipermenore -
jom. Kod žena koje imaju regularne menstrualne ciklu-
se u 20,0% slučajeva izostaje ovulacija.
Najčešći uzrok anovulatornih krvarenja tokom re -
produktivnog perioda žene je sindrom policističnih
jajnika (engl. polycystic ovary syndrome - PCOS). Ređi
uzrok je poremećaj hipotalamo-hipofizne funkcije. Uz
to, i drugi hormonski poremećaji mogu biti praćeni
anovulatornim krvarenjem, kao što su oboljenja tiro -
idne žlezde (hipotireoidizam, hipertireoidizam), nad-
bubrežne žlezde i diabetes mellitus [27,28]. Hiperpro -
laktinemija i povišene vrednosti kortizola (Kušingov
sindrom) takođe mogu dovesti do anovulacije. Ređe,
uzroci su poremećaji ishrane (anoreksija, bulimija),
hronične bolesti, alkoholizam, zloupotreba droga, kao
i stres [4,27,28].
Jatrogeni uzroci
Jatrogeno nastala patološka krvarenja iz materice na-
staju kao posledica uzimanja medikamenata, najčešće
oralnih kontraceptiva, selektivnih modulatora estroge-
nih receptora, GnRH agonista i antagonista, digitalisa
i antikonvulziva. Lekovi izazivaju patološka krvarenja,
bilo remeteći funkciju hipotalamo-hipofizno-gonadne
osovine, bilo izazivajući fluktuacije cirkulišućih nivoa
hormona.
Hiperprolaktinemija može biti posledica dejstva
antipsihotika koji deluju kao dopaminski antagoni-
sti na nivou centralnog nervnog sistema (risperidon)
[4,29]. Patološka krvarenja ove vrste se mogu javiti
kod korisnica kombinovane hormonske kontracepcije
(flasteri, vaginalni prstenovi, pilula), ali i kod korisnica
intrauterinih kontraceptivnih uložaka. Probojna krva-
renja su česta tokom prva tri meseca upotrebe oralnih
Sparić R. i sar.
424 Decembar 2021. | Volumen 2 / Broj 4 | SrpSki medicinSki čaSopiS LekarSke komore
patološko krvarenje iz materice kod žena u reproduktivnom periodu
abnormal uterine bleeding in women of reproductive age
(patches, vaginal rings, contraceptive pills), but also
in women using intrauterine contraceptive implants.
Breakthrough bleeding is common in the first months
of using oral hormone contraceptives and occur in
30.0% to 40.0% of the women using them. This type
of bleeding is most commonly encountered in women
using oral contraceptive pills and hormonal substitu-
tion in perimenopause [30]. Most bleeding manifests
as menorrhagia.
It is important to note that all bleeding in patients
using hormonal contraceptives is not caused by hor -
monal factors. The results of recent studies have shown
that patients using oral contraceptives and experienc -
ing abnormal uterine bleeding also have a high preva-
lence of Chlamydia trachomatis infection, which causes
bleeding in these women. Screening for sexually trans-
mitted diseases should be considered in patients with
abnormal uterine bleeding who use hormonal contra-
ceptives [30].
Endometrial causes
Bleeding occurring in the absence of pathological
changes to the endometrium fall under this category
and was earlier referred to as ‘ovulatory dysfunctional
bleeding’ . Abnormal uterine bleeding may be a man-
ifestation of the disruption in the endometrial repair
mechanism. In these patients, elevated levels of vaso -
dilatory substances (prostacyclin I2 and prostaglandin
E2) are present, as well as decreased levels of vasocon-
strictory substances (endothelin-1 and prostaglandin
2α). These disorders may be primary and secondary,
caused by inflammation or infection of the endometri-
um [4]. Menorrhagia may be the first sign of endome -
tritis in women, in sexually transmitted diseases. Ab -
normal uterine bleeding is frequent in cases of subclin-
ical infection caused by Chlamydia trachomatis. Oth-
er causes include a decrease in the level of estrogen
during treatment with antibiotics and anticonvulsants
[29,31]. Also, this group of disorders includes bleeding
occurring during steroid hormone treatment, such as,
for example, breakthrough bleeding.
Endometrial causes of abnormal uterine bleeding
in women in the reproductive period are diagnosed
only after excluding other pathological processes and
confirming the existence of normal ovulations.
Unclassified causes
Types of abnormal uterine bleeding not covered by the
above-mentioned causes fall under this category, such
as bleeding caused by a foreign body (tampon, pessa-
ry) or trauma. Other causes of bleeding from this group
are chronic endometritis and arteriovenous malforma-
tions [4].
hormonskih kontraceptiva i javljaju se kod 30,0% do
40,0% korisnica. Ova vrsta krvarenja najčešće se sreće
kod korisnica oralnih kontraceptivnih pilula i hormon-
ske supstitucije u perimenopauzi [30]. Većina krvarenja
se manifestuje menoragijom.
Važno je ukazati na to da sva krvarenja kod paci-
jentkinja koje koriste hormonsku kontracepciju nisu
posledica hormonskih faktora. Rezultati novih istraži-
vanja ukazuju na to da pacijentkinje koje koriste oralne
kontraceptive i imaju patološka krvarenja imaju visoku
prevalenciju infekcije Chlamydia-om trachomatis, koja
uzrokuje pojavu krvarenja kod ovih pacijentkinja. Skri-
ning na polno prenosive bolesti treba razmotriti kod
pacijentkinja koje imaju patološka krvarenja i koriste
hormonsku kontracepciju [30].
Endometrijalni uzroci
U ovu kategoriju se svrstavaju krvarenja u odsustvu
patoloških promena endometrijuma, ranije naziva-
na „ovulatorna disfunkcionalna krvarenja“ . Patološka
krvarenja iz materice mogu biti manifestacija pore -
mećaja mehanizama reparacije endometrijuma. Kod
ovih pacijentkinja prisutni su povišeni nivoi vazodila-
tatornih supstanci (prostaciklin I2 i prostaglandin E2) i
sniženi nivoi vazokontriktornih supstanci (endotelin-1
i prostaglandin 2α). Ovi poremećaji mogu biti primarni
i sekundarni, uzrokovani inflamacijom ili infekcijom en-
dometrijuma [4]. Menoragija može biti prvi znak endo -
metritisa kod žena, kod seksualno prenosivih bolesti.
Patološka krvarenja iz materice česta su u slučajevima
subkliničke infekcije uzrokovane Chlamydia-om trac-
homatis. Ostali uzroci uključuju smanjenje nivoa estro-
gena tokom terapije antibioticima i antikonvulzivima
[29,31]. Takođe, u ovu grupu poremećaja spadaju krva-
renja koja se javljaju tokom terapije steroidnim hormo-
nima, kao što je, na primer, probojno krvarenje.
Endometrijalni uzroci patoloških krvarenja iz mate-
rice kod žena u reproduktivnom periodu se dijagnosti-
kuju tek nakon isključivanja ostalih patoloških procesa
i potvrde postojanja normalnih ovulacija.
Neklasifikovani uzroci
U ovu grupu patoloških krvarenja se ubrajaju krvarenja
koja nisu obuhvaćena prethodno opisanim uzrocima,
kao što su krvarenja uzrokovana stranim telom (tam-
pon, pesar) ili traumom. Ostali uzroci krvarenja iz ove
grupe su hronični endometritis i arterio-venske malfor-
macije [4].
Dijagnoza patoloških krvarenja iz materice
Pre sprovođenja bilo koje dijagnostičke procedure ne -
ophodno je isključiti postojanje neprepoznate trudnoće
određivanjem nivoa β-HCG-a u serumu pacijentkinje.
Sparić R. et al.
Serbian JournaL of the m edicaL c hamber | Volume 2 / No. 4 | December 2021. 425
patološko krvarenje iz materice kod žena u reproduktivnom periodu
abnormal uterine bleeding in women of reproductive age
Diagnosis of abnormal uterine bleeding
Before carrying out any diagnostic procedure it is nec-
essary to exclude the existence of an unrecognized
pregnancy by determining the β-HCG level in the se -
rum of the patient.
The diagnostic protocol depends on anamnestic
data and the clinical finding, as well as on the age and
parity of the patient. At the same time the presence
of possible risk factors for the existence of endome -
trial hyperplasia and malignancy must also be taken
into consideration. In all cases of contact bleeding, it
is necessary to perform colposcopy as well as cervical
cytology by Pap smear, and, if necessary, additional di-
agnostics, for the purpose of excluding the existence
of cervical carcinoma.
The first step in the diagnostics is taking a detailed
personal and family medical history (length, cyclicity,
and volume of menstrual bleeding; occurrence of bruis-
es on the skin; nosebleeds; bleeding of gums; postpar-
tum bleeding or bleeding after surgical procedures;
drugs that the patient is on – hormonal medicaments,
anticoagulants, antipsychotics, antidepressants; exis-
tence of accompanying signs and symptoms – change
in body weight, physical activity, premenstrual syn-
drome, dysmenorrhea, dyspareunia, galactorrhea, hir -
sutism, acne). Although subjective, information on the
use of tampons or menstrual pads during menstrua-
tion may offer an estimation on the volume of bleed-
ing. Information on the change of tampons or pads
more often than once in every three hours, as well as
the use of more than 20 menstrual pads during one
menstrual cycle, the need for changing pads or tam-
pons during the night, discharging clots larger than 2.5
cm, bleeding lasting longer than 7 days, indicate pro -
fuse abnormal uterine bleeding.
Clinical examination enables evaluation of patho -
logical changes in the cervix, uterus, and adnexa. It
primarily confirms whether there is irregular uterine
bleeding.
The next step is ultrasound examination of the less-
er pelvis, i.e., the evaluation of the uterus, the thickness
of the endometrium, and the ovaries. Endometrial pol-
yps and submucosal myomas can also be diagnosed
with this examination. In case of unclear findings,
sonohysterography or hysteroscopy is performed, and,
if necessary, fractional explorative curettage. In some
cases, especially in adolescent patients and patients
with an intact hymen, a nuclear magnetic resonance
imaging examination is performed.
If these examinations exclude the existence of
pathological changes in the endometrium, the myo -
metrium, and ovaries, it is necessary to examine
the ovulatory function, as well as to test for other
Dijagnostički protokol zavisi od anamnestičkih
podataka i kliničkog nalaza, kao i od godina starosti,
pariteta, pri čemu se mora imati u vidu i eventualno
prisustvo faktora rizika za postojanje endometrijalne
hiperplazije i maligniteta. U svim slučajevima kontak -
tnog krvarenja, neophodno je uraditi i kolposkopski i
citološki pregled po metodi Papanikolau, a po potrebi i
dopunsku dijagnostiku, u cilju isključivanja postojanja
karcinoma grlića materice.
Prvi korak u dijagnostici jeste uzimanje detaljne
lične i porodične anamneze (dužina trajanja, ciklič -
nost i obim menstrualnog krvarenja; pojava modrica
po koži; krvarenja iz nosa; krvarenja desni; krvarenje
posle porođaja ili operativnih zahvata; uzimanje leko -
va - hormonski preparati, antikoagulansi, antipsihotici,
antidepresivi; postojanje pratećih znakova i simptoma
- promena telesne težine, fizička aktivnost, premenstru-
alni sindrom, dismenoreja, dispareunija, galaktoreja, hi-
rzutizam, akne). Iako subjektivan, podatak o upotrebi
tampona, odnosno uložaka tokom ciklusa, može pružiti
procenu obima krvarenja. Podatak o promeni tampo -
na, odnosno uložaka češće od jednom na tri sata, kao i
upotreba više od 20 tokom jednog ciklusa, potreba za
promenom tampona ili uložaka tokom noći, izbacivanje
ugrušaka većih od 2,5 cm, te krvarenje duže od 7 dana,
ukazuju na obilno patološko krvarenje iz materice.
Klinički pregled omogućava evaluaciju patoloških
promena grlića materice, uterusa i adneksa. Njime se
prvenstveno potvrđuje da li se radi o iregularnom kr -
varenju iz materice.
Nakon toga se izvodi ultrazvučni pregled male kar-
lice, odnosno evaluacija materice, debljine endome -
trijuma i ovarijuma. Ovim pregledom se takođe mogu
dijagnostikovati endometrijalni polipi i submukozni
miomi. U slučaju nejasnih nalaza, radi se sonohistero -
grafija ili histeroskopija, a po potrebi i frakcionirana ek-
splorativna kiretaža. U nekim slučajevima, naročito kod
adolescentkinja i pacijentkinja sa intaktnim himenom,
radi se pregled nuklearnom magnetnom rezonancom.
Ukoliko se ovim pregledima isključi postojanje pato-
loških promena endometrijuma, miometrijuma i jajnika,
neophodno je ispitivanje ovulatorne funkcije, kao i po-
stojanja drugih endokrinopatija i koagulacionih poreme-
ćaja, kao i mikrobiološko ispitivanje (cervikalni i vaginalni
bakteriološki bris, brisevi na Chlamydia-u trachomatis,
Ureaplasma-u urealyticum, Mycoplasma-u hominis).
Određivanjem serumskog progesterona između
22. i 24. dana ciklusa kod žena sa ciklusom na 28 dana,
može se dokumentovati postojanje ovulacije, a vred-
nosti veće od 3 ng/ml ukazuju na postojanje ovulacije.
Kod žena starijih od 40 godina, neophodno je uraditi
dijagnostičku kiretažu u cilju isključivanja karcinoma
endometrijuma [1,2,4,5].
Sparić R. i sar.
426 Decembar 2021. | Volumen 2 / Broj 4 | SrpSki medicinSki čaSopiS LekarSke komore
patološko krvarenje iz materice kod žena u reproduktivnom periodu
abnormal uterine bleeding in women of reproductive age
endocrinopathies and coagulation disorders, and to
perform microbiological testing (cervical and vaginal
bacterial culture swabs, swabs for Chlamydia tracho -
matis, Ureaplasma urealyticum, Mycoplasma hominis).
Establishing the level of serum progesterone be -
tween day 22 and day 24 of the menstrual cycle in
women whose cycle is 28 days, can facilitate the doc -
umenting of the existence of ovulation, with values
above 3 ng/ml indicating the existence of ovulation.
In women above the age of 40 years, it is necessary to
perform diagnostic curettage for the purpose of ex -
cluding endometrial carcinoma [1,2,4,5].
Treatment of abnormal uterine bleeding
The most important step in treating abnormal uterine
bleeding is the diagnosis of the cause of the bleeding.
The therapy is expectative, medicamentous, and sur -
gical. Expectative therapy is advised in case of break -
through bleeding occurring in the first three months of
using oral contraceptives. Polyp treatment is surgical,
and the method of choice is hysteroscopic polypecto -
my. Myomas can be treated with medication as well as
surgically (myomectomy, hysterectomy, blood vessel
embolization, GnRH analogs). Malignant diseases are
treated according to oncological protocols, depending
on the localization of the primary tumor, the histolog-
ical type, and the FIGO stage of the disease. In women
in their reproductive period who experience anovula-
tory bleeding, it is recommended to apply combined
oral contraceptives or intrauterine devices with levo -
norgestrel. In cases of anovulatory bleeding in older
women not interested in reproduction, performing
endometrial ablation or a hysterectomy is an option.
Surgical treatment is performed in patients in whom
medicamentous treatment did not provide the desired
Results
[1,4,5].
Conflict of interest: None declared.
Lečenje patoloških krvarenja iz materice
Najvažniji korak u lečenju patološkog krvarenja je di-
jagnostika uzroka krvarenja. Terapija je ekspektativna,
medikamentna i hirurška. Ekspektativna terapija se
savetuje u slučaju pojave probojnih krvarenja, tokom
prva tri meseca korišćenja oralnih kontraceptiva. Leče-
nje polipa je hirurško, a metoda izbora je histeroskop -
ska polipektomija. Miomi se mogu lečiti medikamen-
tno i hirurški (miomektomija, histerektomija, emboli-
zacija krvnih sudova, GnRH analozi). Maligne bolesti se
leče u skladu sa onkološkim protokolima, u zavisnosti
od lokalizacije primarnog tumora, histološkog tipa i
FIGO stadijuma bolesti. Kod žena u reproduktivnom
periodu sa anovulatornim krvarenjima, savetuje se pri-
mena kombinovanih oralnih kontraceptiva ili intraute-
rinih uložaka sa levonorgestrelom. U slučaju anovula-
tornih krvarenja kod žena starije životne dobi, koje
nisu zainteresovane za rađanje, dolazi u obzir ablacija
endometrijuma i histerektomija. Hirurško lečenje se
primenjuje kod pacijentkinja kod kojih medikamentno
lečenje nije dalo željene rezultate [1,4,5].
Sukob interesa: Nije prijavljen.
LITERATURA / REFERENCES
1. Munro MG, Critchley HO, Fraser IS; FIGO Menstrual Disorders Working Gro -
up. The FIGO classification of causes of abnormal uterine bleeding in the
reproductive years. Fertil Steril. 2011 Jun;95(7):2204-8, 2208.e1-3. doi:
10.1016/j.fertnstert.2011.03.079.
2. Spremović-Rađenović S, Stefanović A, Kadija S, Jeremić K, Sparić R. Classifi -
cation and the diagnostics of abnormal uterine bleeding in nongravid wo -
men of reproductive age: The PALM-COEIN classification system adopted
by the International Federation of Gynecology and Obstetrics. Vojnosanit
Pregl. 2016 Dec;73(12):1154-9. doi: 10.2298/VSP160709289S.
3. Munro MG, Critchley HOD, Fraser IS; FIGO Menstrual Disorders Committee.
The two FIGO systems for normal and abnormal uterine bleeding symptoms
and classification of causes of abnormal uterine bleeding in the reproducti -
ve years: 2018 revisions. Int J Gynaecol Obstet. 2018 Dec;143(3):393-408.
doi: 10.1002/ijgo.12666.
4. Marnach ML, Laughlin-Tommaso SK. Evaluation and Management of
Abnormal Uterine Bleeding. Mayo Clin Proc. 2019 Feb;94(2):326-35. doi:
10.1016/j.mayocp.2018.12.012.
5. Munro MG. Practical aspects of the two FIGO systems for management of
abnormal uterine bleeding in the reproductive years. Best Pract Res Clin
Obstet Gynaecol. 2017 Apr;40:3-22. doi: 10.1016/j.bpobgyn.2016.09.011.
6. Liu Z, Doan QV, Blumenthal P , Dubois RW. A systematic review evaluating
health-related quality of life, work impairment, and health-care costs
and utilization in abnormal uterine bleeding. Value Health. 2007 May-
Jun;10(3):183-94. doi: 10.1111/j.1524-4733.2007.00168.x.
7. Sparic R, Mirkovic L, Malvasi A, Tinelli A. Epidemiology of Uterine Myo -
mas: A Review. Int J Fertil Steril. 2016 Jan-Mar;9(4):424-35. doi: 10.22074/
ijfs.2015.4599.
8. Nijkang NP , Anderson L, Markham R, Manconi F. Endometrial polyps:
Pathogenesis, sequelae and treatment. SAGE Open Med. 2019 May
2;7:2050312119848247. doi: 10.1177/2050312119848247.
9. Salim S, Won H, Nesbitt-Hawes E, Campbell N, Abbott J. Diagnosis and
management of endometrial polyps: a critical review of the literatu -
re. J Minim Invasive Gynecol. 2011 Sep-Oct;18(5):569-81. doi: 10.1016/j.
jmig.2011.05.018.
10. Leyendecker G, Kunz G, Herbertz M, Beil D, Huppert P , Mall G, et al. Uterine
peristaltic activity and the development of endometriosis. Ann N Y Acad
Sci. 2004 Dec;1034:338-55. doi: 10.1196/annals.1335.036.
11. de Bruijn AM, Smink M, Lohle PNM, Huirne JAF , Twisk JWR, Wong C, et al.
Uterine Artery Embolization for the Treatment of Adenomyosis: A Systema-
tic Review and Meta-Analysis. J Vasc Interv Radiol. 2017 Dec;28(12):1629-
42.e1. doi: 10.1016/j.jvir.2017.07.034.
12. Laughlin SK, Stewart EA. Uterine leiomyomas: individualizing the approach
to a heterogeneous condition. Obstet Gynecol. 2011 Feb;117(2 Pt 1):396-
403. doi: 10.1097/AOG.0b013e31820780e3.
Sparić R. et al.
Serbian JournaL of the m edicaL c hamber | Volume 2 / No. 4 | December 2021. 427
patološko krvarenje iz materice kod žena u reproduktivnom periodu
abnormal uterine bleeding in women of reproductive age
13. Sparić R. [Uterine myomas in pregnancy, childbirth and puerperium].
Srp Arh Celok Lek. 2014 Jan-Feb;142(1-2):118-24. Serbian. doi: 10.2298/
sarh1402118s.
14. Tinelli A, Vinciguerra M, Malvasi A, Andjić M, Babović I, Sparić R. Uterine
Fibroids and Diet. Int J Environ Res Public Health. 2021 Jan 25;18(3):1066.
doi: 10.3390/ijerph18031066.
15. Divakar H. Asymptomatic uterine fibroids. Best Pract Res Clin Obstet Gynae-
col. 2008 Aug;22(4):643-54. doi: 10.1016/j.bpobgyn.2008.01.007.
16. Tinelli A, Sparic R, Kadija S, Babovic I, Tinelli R, Mynbaev OA, et al. Myomas:
anatomy and related issues. Minerva Ginecol. 2016 Jun;68(3):261-73.
17. Sparic R, Terzic M, Malvasi A, Tinelli A. Uterine fibroids - clinical presen -
tation and complications. Acta Chir Iugosl 2014;61:41–8. doi: 10.2298/
ACI1403041S.
18. Sparic R, Nejkovic L, Mutavdzic D, Malvasi A, Tinelli A. Conservative surgical
treatment of uterine fibroids. Acta Chir Iugosl 2014;61:11–6. doi: 10.2298/
ACI1404011S.
19. Gupta S, Jose J, Manyonda I. Clinical presentation of fibroids. Best Pract
Res Clin Obstet Gynaecol. 2008 Aug;22(4):615-26. doi: 10.1016/j.bpo -
bgyn.2008.01.008.
20. Manyonda I, Belli AM, Lumsden MA, Moss J, McKinnon W, Middleton LJ,
et al.; FEMME Collaborative Group. Uterine-Artery Embolization or Myome -
ctomy for Uterine Fibroids. N Engl J Med. 2020 Jul 30;383(5):440-51. doi:
10.1056/NEJMoa1914735.
21. See AT, Havenga S. Outcomes of women with postcoital bleeding. Int J
Gynaecol Obstet. 2013 Jan;120(1):88-9. doi: 10.1016/j.ijgo.2012.07.017.
22. Doraiswami S, Johnson T, Rao S, Rajkumar A, Vijayaraghavan J, Panicker
VK. Study of endometrial pathology in abnormal uterine bleeding. J Obstet
Gynaecol India. 2011 Aug;61(4):426-30. doi: 10.1007/s13224-011-0047-2.
23. Haidopoulos D, Simou M, Akrivos N, Rodolakis A, Vlachos G, Fotiou S, et
al. Risk factors in women 40 years of age and younger with endometrial
carcinoma. Acta Obstet Gynecol Scand. 2010 Oct;89(10):1326-30. doi:
10.3109/00016349.2010.515666.
24. James AH, Manco-Johnson MJ, Yawn BP , Dietrich JE, Nichols WL. Von Wille-
brand disease: key points from the 2008 National Heart, Lung, and Blood
Institute guidelines. Obstet Gynecol. 2009 Sep;114(3):674-8. doi: 10.1097/
AOG.0b013e3181b191ea.
25. Deligeoroglou E, Karountzos V. Abnormal Uterine Bleeding including co -
agulopathies and other menstrual disorders. Best Pract Res Clin Obstet
Gynaecol. 2018 Apr;48:51-61. doi: 10.1016/j.bpobgyn.2017.08.016.
26. Elmaoğulları S, Aycan Z. Abnormal Uterine Bleeding in Adolescents. J Clin
Res Pediatr Endocrinol. 2018 Jul 31;10(3):191-7 . doi: 10.4274/jcrpe.0014.
27. Thakur M, Maharjan M, Tuladhar H, Dwa Y, Bhandari S, Maskey S, et al.
Thyroid Dysfunction in Patients with Abnormal Uterine Bleeding in a Ter -
tiary Care Hospital: A Descriptive Cross-sectional Study. JNMA J Nepal Med
Assoc. 2020 May 30;58(225):333-7 . doi: 10.31729/jnma.5033.
28. Delitala AP , Capobianco G, Delitala G, Cherchi PL, Dessole S. Polycystic ovary
syndrome, adipose tissue and metabolic syndrome. Arch Gynecol Obstet.
2017 Sep;296(3):405-19. doi: 10.1007/s00404-017-4429-2.
29. Joffe H, Hayes FJ. Menstrual cycle dysfunction associated with neurologic
and psychiatric disorders: their treatment in adolescents. Ann N Y Acad Sci.
2008;1135:219-29. doi: 10.1196/annals.1429.030.
30. McCarthy KJ, Gollub EL, Ralph L, van de Wijgert J, Jones HE. Hormonal
Contraceptives and the Acquisition of Sexually Transmitted Infections: An
Updated Systematic Review. Sex Transm Dis. 2019 May;46(5):290-6. doi:
10.1097 /OLQ.0000000000000975.
31. Parkash V, Fadare O, Tornos C, McCluggage WG. Committee Opinion No. 631:
Endometrial Intraepithelial Neoplasia. Obstet Gynecol. 2015 Oct;126(4):897 .
doi: 10.1097 /AOG.0000000000001071.